10x Genomics Lifts 2026 Sales Outlook To $625 Million–$635 Million As Quarterly Loss Narrows

Consumables sales increased while instrument revenue fell, and lower inventory markdowns helped improve gross margin.

Share
10x Genomics Lifts 2026 Sales Outlook To $625 Million–$635 Million As Quarterly Loss Narrows

10x Genomics, which makes instruments, consumables and software for single-cell and tissue research, raised its 2026 revenue outlook Thursday to $625 million–$635 million, from $610 million–$630 million, according to its earnings release accompanying an SEC filing. Third-quarter sales rose 1%, but lower costs and a changed product mix produced a larger improvement in its losses.

Consumables Grow, Instrument Sales Fall

Quarterly revenue reached $150.7 million, compared with $149.0 million a year earlier. TXG shares rose about 2% to $59.30 in Friday trading.

Consumables brought in $134.327 million, versus $127.892 million a year earlier. Within that business, products used to map biology within tissue generated $41.188 million, compared with $35.373 million; single-cell consumables generated $93.139 million, versus $92.519 million.

Instrument revenue moved the other way, falling to $6.858 million from $11.999 million. Services revenue increased to $9.025 million from $8.128 million.

The annual outlook carries an important distinction: management expects growth of 4%–6% when non-recurring patent-settlement license and royalty revenue is excluded from both 2026 and 2025. For the first nine months, total revenue was $452.546 million versus $476.793 million, while products and services revenue increased to $449.200 million from $430.999 million.

Lower Markdowns Improve Gross Margin

The company retained 75% of sales after product and service costs, up from 67% a year earlier. Management attributed the improvement mainly to smaller inventory markdowns and the mix of products sold.

Operating expenses fell 3% to $129.0 million from $132.5 million. Reduced personnel and laboratory-equipment spending outweighed an increase in litigation costs.

The operating loss narrowed to $16.1 million from $32.2 million. The net loss also shrank, to $19.4 million from $27.5 million, with the per-share loss declining to $0.15 from $0.22.

Atera Ships, Sentira Adds AI Analysis

The business serves academic and government researchers as well as biopharmaceutical and biotechnology institutions. Its Chromium platform examines individual cells; Visium and Xenium help researchers locate molecules within tissue.

10x began worldwide commercial shipments of Atera and introduced Sentira, a cloud-based tool for analyzing biological datasets. Sentira uses NVIDIA computing to process spatial data and Anthropic’s Claude for AI analysis of single-cell data.

Serge Saxonov, co-founder and CEO of 10x Genomics, connected broader business results to consumables: “We were also encouraged with the results across our broader business, driven by continued strength in consumables.”

10x ended September with $575.7 million in cash, cash equivalents and marketable securities, alongside a smaller quarterly operating loss.

Sources

More on 10x Genomics

All 10x Genomics (TXG) coverage →